Phase I/II safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab in metastatic melanoma patients

被引：0
|
作者：
Johnson, Daniel Johnson H. [1 ]
Lecagoonporn, Srisuda [1 ]
Bernatchez, Chantale [1 ]
Haymaker, Cara [1 ]
Bentebibel, Salah [1 ]
Uemura, Marc [1 ]
Yee, Cassian [1 ]
Amaria, Rodabe [1 ]
Patel, Sapna [1 ]
Tawbi, Hussein [1 ]
Glitza, Isabella [1 ]
Davies, Michael A. [1 ]
Wong, Michael K. [1 ]
Hwu, Wen-Jen [1 ]
Hwu, Patrick [1 ]
Overwijk, Willem [1 ]
Diab, Adi [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P230
引用
收藏
页数：1
相关论文
共 43 条
  • [1] Phase I/II dose escalation and expansion cohort safety and efficacy study of image guided intratumoral CD40 agonistic monoclonal antibody APX005M in combination with systemic pembrolizumab for treatment naive metastatic melanoma.
    Johnson, Daniel H.
    Bentebibel, Salah E.
    Lecagoonporn, Srisuda
    Bernatchez, Chantale
    Haymaker, Cara L.
    Murthy, Ravi
    Tam, Alda
    Yee, Cassian
    Amaria, Rodabe Navroze
    Patel, Sapna Pradyuman
    Tawbi, Hussein Abdul-Hassan
    Glitza, Isabella Claudia
    Davies, Michael A.
    Hwu, Wen-Jen
    Hwu, Patrick
    Overwijk, Willem W.
    Diab, Adi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinoma
    Reni, Michele
    LANCET ONCOLOGY, 2021, 22 (01): : 10 - 11
  • [3] Phase 1 study to evaluate the safety and tolerability of the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors
    Bendell, Johanna C.
    Fakih, Marwan
    Infante, Jeffrey R.
    Bajor, David Lawrence
    Cristea, Mihaela C.
    Tremblay, Thomas
    Trifan, Ovidiu C.
    Vonderheide, Robert H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Phase 1 study to evaluate the safety and tolerability of the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors
    Fakih, Marwan
    Bajor, David
    Mamtani, Ronac
    Tremblay, Thomas
    Trifan, Ovid
    Vonderheide, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [5] A study to evaluate the safety and efficacy of the CD40 agonistic antibody APX005M in combination with nivolumab in subjects with non-small cell lung cancer and subjects with metastatic melanoma
    Garland, Linda
    Salgia, Ravi
    Johnson, Melissa
    Weise, Amy
    Linette, Gerald
    Tremblay, Thomas
    Trifan, Ovid
    Edelman, Martin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [6] Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC)
    Kluger, Harriet
    Weiss, Sarah A.
    Olszanski, Anthony J.
    Schuchter, Lynn
    Linette, Gerald P.
    Garland, Linda
    Iannotti, Nicholas O.
    Johnson, Melissa
    Avsar, Emin
    Srivastava, Minu K.
    Trifan, Ovid C.
    Edelman, Martin J.
    CANCER RESEARCH, 2019, 79 (13)
  • [7] PHASE II OF CD40 AGONISTIC ANTIBODY SOTIGALIMAB (APX005M) IN COMBINATION WITH NIVOLUMAB IN SUBJECTS WITH METASTATIC MELANOMA WITH CONFIRMED DISEASE PROGRESSION ON ANTI-PD-1 THERAPY
    Weiss, Sarah
    Sznol, Mario
    Shaheen, Montaser
    Berciano-Guerrero, Miguel-Angel
    Felip, Enriqueta
    Rodriguez-Abreu, Delvys
    Arance, Ana Maria
    Boni, Valentina
    Linette, Gerald
    Schuchter, Lynn
    Gonzalez-Cao, Maria
    Iannotti, Nicholas
    Ganti, Apar Kishor
    Hauke, Ralph
    Berrocal, Alfonso
    Filbert, Erin
    Kluger, Harriet
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A422 - A422
  • [8] A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
    Weiss, Sarah A.
    Sznol, Mario
    Shaheen, Montaser
    Berciano-Guerrero, Miguel-Angel
    Couselo, Eva Munoz
    Rodriguez-Abreu, Delvys
    Boni, Valentina
    Schuchter, Lynn M.
    Gonzalez-Cao, Maria
    Arance, Ana
    Wei, Wei
    Ganti, Apar Kishor
    Hauke, Ralph J.
    Berrocal, Alfonso
    Iannotti, Nicholas O.
    Hsu, Frank J.
    Kluger, Harriet M.
    CLINICAL CANCER RESEARCH, 2024, 30 (01) : 74 - 81
  • [9] A phase 1b/2 study of CD40 agonistic monoclonal antibody (APX005M) together with gemcitabine and nab-paclitaxel with or without nivolumab in untreated metastatic pancreatic adenocarcinoma patients
    O'Hara, Mark
    Mick, Rosemarie
    Lyman, Jaclyn
    Xu, Jingying
    Hosseini, Maryam
    LaVallee, Theresa
    Gherardini, Pier Federico
    Vance, Barbara
    Trifan, Ovid
    Dugan, Ute
    Shalabi, Aiman
    Ibrahim, Ramy
    Vonderheide, Robert
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [10] CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
    O'Hara, Mark H.
    O'Reilly, Eileen M.
    Varadhachary, Gauri
    Wolff, Robert A.
    Wainberg, Zev A.
    Ko, Andrew H.
    Fisher, George
    Rahma, Osama
    Lyman, Jaclyn P.
    Cabanski, Christopher R.
    Mick, Rosemarie
    Gherardini, Pier Federico
    Kitch, Lacey J.
    Xu, Jingying
    Samuel, Theresa
    Karakunnel, Joyson
    Fairchild, Justin
    Bucktrout, Samantha
    LaVallee, Theresa M.
    Selinsky, Cheryl
    Till, Jacob E.
    Carpenter, Erica L.
    Alanio, Cecile
    Byrne, Katelyn T.
    Chen, Richard O.
    Trifan, Ovid C.
    Dugan, Ute
    Horak, Christine
    Hubbard-Lucey, Vanessa M.
    Wherry, E. John
    Ibrahim, Ramy
    Vonderheide, Robert H.
    LANCET ONCOLOGY, 2021, 22 (01): : 118 - 131
12345